As AbbVie and Soliton shake hands on a $550M merger, the FTC says 'not so fast'
Back in May, AbbVie’s Allergan Aesthetics unit signed away $550 million in cash to scoop up drugmaker Soliton and its body sculpting device Resonic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
